These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
190 related articles for article (PubMed ID: 11709334)
1. Urinary excretion and bactericidal activities of gemifloxacin and ofloxacin after a single oral dose in healthy volunteers. Naber CK; Hammer M; Kinzig-Schippers M; Sauber C; Sörgel F; Bygate EA; Fairless AJ; Machka K; Naber KG Antimicrob Agents Chemother; 2001 Dec; 45(12):3524-30. PubMed ID: 11709334 [TBL] [Abstract][Full Text] [Related]
2. Concentrations in plasma, urinary excretion, and bactericidal activity of linezolid (600 milligrams) versus those of ciprofloxacin (500 milligrams) in healthy volunteers receiving a single oral dose. Wagenlehner FM; Wydra S; Onda H; Kinzig-Schippers M; Sörgel F; Naber KG Antimicrob Agents Chemother; 2003 Dec; 47(12):3789-94. PubMed ID: 14638484 [TBL] [Abstract][Full Text] [Related]
3. Urinary bactericidal activity, urinary excretion and plasma concentrations of gatifloxacin (400 mg) versus ciprofloxacin (500 mg) in healthy volunteers after a single oral dose. Boy D; Well M; Kinzig-Schippers M; Sörgel F; Ankel-Fuchs D; Naber KG Int J Antimicrob Agents; 2004 Mar; 23 Suppl 1():S6-16. PubMed ID: 15037323 [TBL] [Abstract][Full Text] [Related]
4. In vitro activity of gatifloxacin compared with gemifloxacin, moxifloxacin, trovafloxacin, ciprofloxacin and ofloxacin against uropathogens cultured from patients with complicated urinary tract infections. Naber KG; Hollauer K; Kirchbauer D; Witte W Int J Antimicrob Agents; 2000 Nov; 16(3):239-43. PubMed ID: 11091042 [TBL] [Abstract][Full Text] [Related]
5. Urinary concentrations and bactericidal activities of newer fluoroquinolones in healthy volunteers. Stein GE; Schooley S Int J Antimicrob Agents; 2004 Aug; 24(2):168-72. PubMed ID: 15288316 [TBL] [Abstract][Full Text] [Related]
6. Concentrations in plasma, urinary excretion and bactericidal activity of levofloxacin (500 mg) versus ciprofloxacin (500 mg) in healthy volunteers receiving a single oral dose. Wagenlehner FM; Kinzig-Schippers M; Sörgel F; Weidner W; Naber KG Int J Antimicrob Agents; 2006 Dec; 28(6):551-9. PubMed ID: 17101261 [TBL] [Abstract][Full Text] [Related]
7. Antibacterial properties of gemifloxacin and trovafloxacin in urine ex vivo: phase I study. García-Calvo G; Parra A; Aguilar L; Ponte C; Giménez MJ; Carcas A; Kinzig-Schippers M; Soriano F Antimicrob Agents Chemother; 2001 Jun; 45(6):1876-8. PubMed ID: 11353641 [TBL] [Abstract][Full Text] [Related]
8. Urinary bactericidal activity and pharmacokinetics of enoxacin versus norfloxacin and ciprofloxacin in healthy volunteers after a single oral dose. Well M; Naber KG; Kinzig-Schippers M; Sörgel F Int J Antimicrob Agents; 1998 Apr; 10(1):31-8. PubMed ID: 9624541 [TBL] [Abstract][Full Text] [Related]
9. Urinary excretion and bactericidal activities of a single oral dose of 400 milligrams of fleroxacin versus a single oral dose of 800 milligrams of pefloxacin in healthy volunteers. Naber KG; Theuretzbacher U; Kinzig M; Savov O; Sörgel F Antimicrob Agents Chemother; 1998 Jul; 42(7):1659-65. PubMed ID: 9661000 [TBL] [Abstract][Full Text] [Related]
10. Comparative in vitro activity of gemifloxacin, ciprofloxacin, levofloxacin and ofloxacin in a North American surveillance study. Hoban DJ; Bouchillon SK; Johnson JL; Zhanel GG; Butler DL; Miller LA; Poupard JA; Diagn Microbiol Infect Dis; 2001; 40(1-2):51-7. PubMed ID: 11448564 [TBL] [Abstract][Full Text] [Related]
11. Urinary excretion and bactericidal activity of intravenous ciprofloxacin compared with oral ciprofloxacin. Naber KG; Theuretzbacher U; Moneva-Koucheva G; Stass H Eur J Clin Microbiol Infect Dis; 1999 Nov; 18(11):783-9. PubMed ID: 10614952 [TBL] [Abstract][Full Text] [Related]
12. Urine bactericidal activity after administration of gemifloxacin and trovafloxacin single doses in a phase I study. García-Calvo G; Parra A; Ponte C; Soriano F; Giménez MJ; Aguilar L Int J Antimicrob Agents; 2002 Dec; 20(6):477-80. PubMed ID: 12458147 [No Abstract] [Full Text] [Related]
13. In vitro activity of gemifloxacin against a broad range of recent clinical isolates from the USA. McCloskey L; Moore T; Niconovich N; Donald B; Broskey J; Jakielaszek C; Rittenhouse S; Coleman K J Antimicrob Chemother; 2000 Apr; 45 Suppl 1():13-21. PubMed ID: 10824027 [TBL] [Abstract][Full Text] [Related]
14. Comparative in vitro activities of five quinolone antibiotics, including gemifloxacin, against clinical isolates. Gönüllü N; Aktaş Z; Salcioglu M; Bal C; Ang O Clin Microbiol Infect; 2001 Sep; 7(9):499-503. PubMed ID: 11678934 [TBL] [Abstract][Full Text] [Related]
15. Pharmacodynamics of moxifloxacin and levofloxacin against Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella pneumoniae and Escherichia coli: simulation of human plasma concentrations after intravenous dosage in an in vitro kinetic model. Odenholt I; Cars O J Antimicrob Chemother; 2006 Nov; 58(5):960-5. PubMed ID: 16936293 [TBL] [Abstract][Full Text] [Related]
16. Comparative in vitro potency of gemifloxacin and fluoroquinolones against recent European clinical isolates from a global surveillance study. Hoban DJ; Bouchillon SK; Johnson JL; Zhanel GG; Butler DL; Miller LA; Poupard JA; Eur J Clin Microbiol Infect Dis; 2001 Nov; 20(11):814-9. PubMed ID: 11783700 [TBL] [Abstract][Full Text] [Related]